Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Downregulated ZNF132 predicts unfavorable outcomes in breast Cancer via Hypermethylation modification

Fig. 5

Aberrant methylation of ZNF132 in BC. a Expression of 3 DNA methyltransferases (DNMT1, DNMT3A and DNMT3B) in ZNF132High and ZNF132Low group (n = 1104). b MethHC analysis demonstrated that the methylation level of ZNF132 in BC tissues was significantly higher than the normal sample. c Methylation level of ZNF132 in different CpG sites between BC tissues and matched normal tissues. d ZNF132 methylation level was negatively correlated with its gene expression. e Promoter methylation of ZNF132 in BC cell lines was determined using the MSP assay. In vitro methylated DNA as a positive control for methylated gene (Pos); Bisulfite-modified normal leukocyte DNA as a positive control for unmethylated gene (Neg); Mk, DNA marker; M, methylated gene; U, unmethylated gene; 231, MDA-MB-231; MCF7; 1937, HCC1937; T47D; 453, MDA-MB-453; 4475, DU4475. f mRNA level of ZNF132 was partially restored by 5-Aza-dC including MDA-MB-231, MCF7, HCC1937, and MDA-MB-453. g The protein level of ZNF132 was partially restored by 5-Aza-dC, including MDA-MB-231, MCF7, and HCC1937. Ctr, Control; 5-Aza, 5-Aza-Dc. Statistically significant differences were indicated: *P < 0.01, **P < 0.001, ***P < 0.0001

Back to article page